In recent years, the pharmaceutical industry has seen tremendous changes in the way it is expected to deliver new drugs to market: being under increasing pressure to expedite the development of
new therapies, to decrease clinical study duration, and to drive new treatments through their clinical phases as quickly, safely and cost-efficiently as possible. Frank Andrew, PCI, discusses how such changes have required the industry to re-evaluate and rethink long-standing approaches to drug development and commercialisation.